From: FeV1 and BMI influence King’s Sarcoidosis Questionnaire score in sarcoidosis patients
Whole cohort | Female cohort (n = 97) | Male cohort (n = 103) | |||||
---|---|---|---|---|---|---|---|
Median or Mean ± SD | IQR | Median or Mean ± SD | IQR | Median or Mean ± SD | IQR | p (female vs male) | |
Age | 53.3 ± 12.7 | 55.0 ± 12.4 | 51.8 ± 12.8 | 0.08 | |||
BMI | 28.0 ± 5.3 | 27.5 ± 4.9 | 28.4 ± 5.7 | 0.42 | |||
FVC | 98.4 | 83.2–108.4 | 98.7 | 84.7–106.3 | 98.3 | 83.3–109.8 | 0.91 |
TLC | 86.3 | 75.1–95.8 | 85.0 | 74.3–95.9 | 87.5 | 75.3–95.0 | 0.50 |
DLCOsb | 80.2 | 69.9–90.9 | 80.4 | 71.3–89.4 | 78.8 | 67.9–91.2 | 0.80 |
FEV1 | 85.8 | 74.5–99.1 | 86.8 | 75.6–98.7 | 84.6 | 74.4–99.1 | 0.64 |
GHS | 67.9 | 51.9–80.2 | 69.8 | 58.0–81.1 | 64.2 | 49.1–79.3 | 0.15 |
GHS L | 73.0 | 56.7–82.2 | 74.2 | 59.1–84.0 | 68.0 | 53.4–80.9 | 0.28 |
GHS E | 69.4 | 54.4–80.6 | 71.7 | 57.8–82.1 | 68.3 | 50.0–80.6 | 0.30 |
GHS S | 72.1 | 60.0–83.6 | 75.4 | 63.6–85.0 | 67.9 | 55.7–80.7 | 0.06 |
GHS LS | 73.1 | 59.7–83.7 | 77.4 | 62.3–85.4 | 70.8 | 50.8–81.6 | 0.15 |
GHS LM | 72.5 | 59.2–82.0 | 76.8 | 62.2–83.2 | 69.4 | 54.6–81.9 | 0.14 |
GHS SM | 72.3 | 61.6–82.7 | 76.3 | 67.6–84.4 | 68.8 | 57.8–79.2 | 0.02 |
GHS LSM | 74.3 | 60.7–83.3 | 78.4 | 64.7–84.5 | 71.8 | 58.4–80.0 | 0.06 |
LUNG | 77.8 | 58.3–93.1 | 76.4 | 58.3–93.1 | 77.8 | 58.3–93.1 | 0.88 |
MED | 84.9 | 54.6–100 | 84.9 | 67.7–100 | 77.3 | 54.6–100 | 0.13 |
SKIN | 88.2 | 70.6–100 | 94.1 | 70.6–100 | 82.4 | 70.6–100 | 0.15 |
EYES | 77.0 | 52.7–93.2 | 77.0 | 53.4–93.2 | 73.0 | 52.7–93.2 | 0.63 |
Borg | 0.5 | 0.0–2.0 | 0.5 | 0.0–2.0 | 0.5 | 0.0–2.8 | 0.50 |
sIL2R | 513.5 | 380–713 | 506.5 | 378.8–679.5 | 528.5 | 380–735 | 0.59 |
Neopterin | 11.5 | 8.4–16.4 | 12.2 | 9.0–16.3 | 10.3 | 7.7–16.5 | 0.09 |
ACE | 35.4 | 22.7–48.9 | 39.1 | 25.6–51.2 | 28.8 | 20.6–43.8 | 0.06 |